NASDAQ:DNLI - Denali Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.72 +0.04 (+0.19 %) (As of 05/20/2019 06:36 AM ET)Previous Close$20.68Today's Range$20.12 - $21.0652-Week Range$12.32 - $28.86Volume448,990 shsAverage Volume370,587 shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California. Receive DNLI News and Ratings via Email Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI Previous Symbol CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone650-866-8548Debt Debt-to-Equity Ratio0.14 Current Ratio11.55 Quick Ratio11.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$129.16 million Price / Sales15.32 Cash FlowN/A Price / Cash FlowN/A Book Value$5.41 per share Price / Book3.83Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-36,240,000.00 Net Margins-38.84% Return on Equity-10.23% Return on Assets-8.40%Miscellaneous Employees179 Outstanding Shares95,480,000Market Cap$1.98 billion Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions What is Denali Therapeutics' stock symbol? Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI." How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc (NASDAQ:DNLI) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. The company earned $4.21 million during the quarter, compared to analyst estimates of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. View Denali Therapeutics' Earnings History. When is Denali Therapeutics' next earnings date? Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Denali Therapeutics. What price target have analysts set for DNLI? 2 equities research analysts have issued 1-year price objectives for Denali Therapeutics' stock. Their forecasts range from $25.00 to $26.00. On average, they expect Denali Therapeutics' share price to reach $25.50 in the next year. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Denali Therapeutics. What is the consensus analysts' recommendation for Denali Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics. Has Denali Therapeutics been receiving favorable news coverage? News articles about DNLI stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Denali Therapeutics earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Denali Therapeutics' key competitors? Some companies that are related to Denali Therapeutics include BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI) and Audentes Therapeutics (BOLD). What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Kratos Defense & Security Solutions (KTOS), Pretium Resources (PVG), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Pretium Resources (PVG), Esperion Therapeutics (ESPR) and Crispr Therapeutics (CRSP). Who are Denali Therapeutics' key executives? Denali Therapeutics' management team includes the folowing people: Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)Mr. Steve E. Krognes, CFO & Treasurer (Age 50)Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46) When did Denali Therapeutics IPO? (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.56%), FMR LLC (5.75%), BlackRock Inc. (4.77%), FIL Ltd (1.33%), Wasatch Advisors Inc. (0.86%) and Geode Capital Management LLC (0.81%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics. Which major investors are selling Denali Therapeutics stock? DNLI stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, Citigroup Inc., Morgan Stanley, BlackRock Inc., California State Teachers Retirement System, Wells Fargo & Company MN and American International Group Inc.. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics. Which major investors are buying Denali Therapeutics stock? DNLI stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Federated Investors Inc. PA, Geode Capital Management LLC, Goldman Sachs Group Inc., Baillie Gifford & Co., Neuberger Berman Group LLC, Spark Investment Management LLC and Dynamic Technology Lab Private Ltd. View Insider Buying and Selling for Denali Therapeutics. How do I buy shares of Denali Therapeutics? Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Denali Therapeutics' stock price today? One share of DNLI stock can currently be purchased for approximately $20.72. How big of a company is Denali Therapeutics? Denali Therapeutics has a market capitalization of $1.98 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe. What is Denali Therapeutics' official website? The official website for Denali Therapeutics is http://www.denalitherapeutics.com. How can I contact Denali Therapeutics? Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548. MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 263 (Vote Outperform)Underperform Votes: 285 (Vote Underperform)Total Votes: 548MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.